Ferreira SH: A bradykinin-potentiating factor (BPF) present in venom of Bothrops jararca. Br J Pharmacol 1965;24:163-169.
Ferguson RK, Brunner HR, Turin GA, et al: A specific orally active inhibitor of converting enzyme in man. Lancet 1977;1:775-778.
Swartz SL, Williams GH, Hollenberg NK, et al: Endocrine profile in the long-term phase of converting enzyme inhibition. Clin Pharmacol Ther 1980;28:499-508.
Johns DW, Baker KM, Ayers CR, et al: Acute and chronic effect of captopril in hypertensive patients. Hypertension 1980;2:567-575.
Case DB, Atlas SA, Laragh JH, et al: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor, SQ14225, captopril, in hypertensive patients. Prog Cardiovasc Dis 1978;21:195-206.
Brunner HR, Gavras H, Waeber B, et al: Oral angiotensin converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1979;90:19-23.
Jenkins AC, McKinstry DN: Review of clinical studies of hypertensive patients treated with captopril. Med J Aust 1979;2(
Friedlander DH: Comparison of captopril with propranolol in the treatment of essential hypertension. Med J Aust 1979;2(
Ferguson RK, Vlasses DH, Koplin JR, et al: Captopril in severe treatment-resistant hypertension. Am Heart J 1980;99:579-585.
Atkinson AB, Brown JJ, Lever AF, et al: Combined treatment of severe intractable hypertension with captopril and diuretics. Lancet 1980;2:105-107.
Banks RA, Markandund ND, Roulston JE, et al: Differing effects of sodium restriction, spironolactone, propranolol with captopril in black and white patients with hypertension, abstracted. Read before the International Society of Hypertension, Milan, Italy, June 1-3, 1981.
Johnston CI, McGrath BD, Millar JA, et al: Long-term effects of captopril (SQ 14225) on blood pressure and hormone levels in essential hypertension. Lancet 1977;2:493-495.
Laragh JH, Case DB, Atlas SA, et al: Captopril compared with other anti-renin system agents in hypertensive patients: Its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 1980;2:586-593.
Vaughan ED Jr, Carey RM, Ayers CR, et al: Hemodialysis-resistant hypertension: Control with orally active inhibitor of angiotensin converting enzyme. J Clin Endocrinol Metab 1979;48:869-871.
D'Angelo WA, Lopez-Overjo JA, Soral SD, et al: Early versus late treatment of sclerodermal renal crisis and malignant hypertension with captopril, abstracted. Arthritis Rheum 1980;23:664.
Dzau VJ, Colucci WS, Williams GH, et al: Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980;302:1373-1379.
Faxon DP, Halperin JL, Creager MA, et al: Angiotensin inhibition in severe heart failure: Acute central and hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J 1981;101:548-556.
Linjen P, Fagard P, Staessen J, et al: Dose response of captopril therapy on hypertension. Clin Pharmacol Ther 1980;28:310-315.
Captopril: Benefit and risks in severe hypertension. Lancet 1980;2:129-130.
Gavras I, Graff LG, Rose BD, et al: Fatal pancytopenia associated with the use of captopril. Ann Intern Med 1981;94:58-59.
Case DB, Atlas SA, Mourandian JA, et al: Proteinuria during long-term captopril therapy. JAMA 1980;244:346-349.
Hoorntje SJ, Kallenberg CGM, Weening JJ, et al: Immune-complex glomerulopathy in patients treated with captopril. Lancet 1980;1:1212-1214.
McNeil JJ, Anderson A, Christophidis N, et al: Taste loss associated with oral captopril treatment. Br Med J 1979;2:1555-1556.